FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090907917> ?p ?o ?g. }

• W2090907917 endingPage "2118" @default.
• W2090907917 startingPage "2110" @default.
• W2090907917 abstract "BACKGROUND. The antiepileptic agent, gabapentin, has been demonstrated to relieve symptoms of peripheral neuropathy due to various etiologies. On the basis of these data, a multicenter, double-blind, placebo-controlled, crossover, randomized trial was conducted to evaluate the effect of gabapentin on symptoms of chemotherapy-induced peripheral neuropathy (CIPN). METHODS. Patients with symptomatic CIPN who complained of ‘average’ daily pain scores of either 1) ≥4 on a 0–10 numerical rating scale (NRS); or 2) ≥1 on the 0–3 Eastern Cooperative Oncology Group neuropathy scale (ENS) were eligible (higher numbers indicate greater severity of symptoms in both scales). Patients were randomized to receive gabapentin (target dose, 2700 mg) or placebo for 6 weeks. Crossover occurred after a 2-week washout period. CIPN-related symptoms were evaluated weekly by questionnaires. Statistical methods followed established methods for crossover designs, including Student t tests to compare average intrapatient differences between treatments and linear models to adjust for potential concomitant covariates. RESULTS. There were 115 patients who were randomly assigned to the treatment or control arm. Both groups were well matched by symptoms at study entry. Changes in symptom severity were statistically similar between the 2 groups during the study. Adverse events were mild and similar in both groups. CONCLUSIONS. This trial failed to demonstrate any benefit to using gabapentin to treat symptoms caused by CIPN. Cancer 2007. © 2007 American Cancer Society." @default.
• W2090907917 created "2016-06-24" @default.
• W2090907917 creator A5008767553 @default.
• W2090907917 creator A5013202100 @default.
• W2090907917 creator A5015875841 @default.
• W2090907917 creator A5020093978 @default.
• W2090907917 creator A5025947614 @default.
• W2090907917 creator A5057289307 @default.
• W2090907917 creator A5060096861 @default.
• W2090907917 creator A5067856866 @default.
• W2090907917 creator A5072257104 @default.
• W2090907917 creator A5081957836 @default.
• W2090907917 date "2007-01-01" @default.
• W2090907917 modified "2023-10-18" @default.
• W2090907917 title "Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy" @default.
• W2090907917 cites W1794352460 @default.
• W2090907917 cites W180761474 @default.
• W2090907917 cites W1950229121 @default.
• W2090907917 cites W1967936620 @default.
• W2090907917 cites W1974542461 @default.
• W2090907917 cites W1991407170 @default.
• W2090907917 cites W1994799351 @default.
• W2090907917 cites W1995772131 @default.
• W2090907917 cites W1999408762 @default.
• W2090907917 cites W2000366267 @default.
• W2090907917 cites W2017865504 @default.
• W2090907917 cites W2027053525 @default.
• W2090907917 cites W2035062443 @default.
• W2090907917 cites W2039982019 @default.
• W2090907917 cites W2048497026 @default.
• W2090907917 cites W2054260401 @default.
• W2090907917 cites W2060987807 @default.
• W2090907917 cites W2074041943 @default.
• W2090907917 cites W2076668534 @default.
• W2090907917 cites W2094702933 @default.
• W2090907917 cites W2101871493 @default.
• W2090907917 cites W2102368782 @default.
• W2090907917 cites W2132309748 @default.
• W2090907917 cites W2138407894 @default.
• W2090907917 cites W2140464421 @default.
• W2090907917 cites W2141918005 @default.
• W2090907917 cites W2152953447 @default.
• W2090907917 cites W2158234609 @default.
• W2090907917 cites W2167805334 @default.
• W2090907917 doi "https://doi.org/10.1002/cncr.23008" @default.
• W2090907917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17853395" @default.
• W2090907917 hasPublicationYear "2007" @default.
• W2090907917 type Work @default.
• W2090907917 sameAs 2090907917 @default.
• W2090907917 citedByCount "297" @default.
• W2090907917 countsByYear W20909079172012 @default.
• W2090907917 countsByYear W20909079172013 @default.
• W2090907917 countsByYear W20909079172014 @default.
• W2090907917 countsByYear W20909079172015 @default.
• W2090907917 countsByYear W20909079172016 @default.
• W2090907917 countsByYear W20909079172017 @default.
• W2090907917 countsByYear W20909079172018 @default.
• W2090907917 countsByYear W20909079172019 @default.
• W2090907917 countsByYear W20909079172020 @default.
• W2090907917 countsByYear W20909079172021 @default.
• W2090907917 countsByYear W20909079172022 @default.
• W2090907917 countsByYear W20909079172023 @default.
• W2090907917 crossrefType "journal-article" @default.
• W2090907917 hasAuthorship W2090907917A5008767553 @default.
• W2090907917 hasAuthorship W2090907917A5013202100 @default.
• W2090907917 hasAuthorship W2090907917A5015875841 @default.
• W2090907917 hasAuthorship W2090907917A5020093978 @default.
• W2090907917 hasAuthorship W2090907917A5025947614 @default.
• W2090907917 hasAuthorship W2090907917A5057289307 @default.
• W2090907917 hasAuthorship W2090907917A5060096861 @default.
• W2090907917 hasAuthorship W2090907917A5067856866 @default.
• W2090907917 hasAuthorship W2090907917A5072257104 @default.
• W2090907917 hasAuthorship W2090907917A5081957836 @default.
• W2090907917 hasConcept C126322002 @default.
• W2090907917 hasConcept C134018914 @default.
• W2090907917 hasConcept C138496976 @default.
• W2090907917 hasConcept C142724271 @default.
• W2090907917 hasConcept C15744967 @default.
• W2090907917 hasConcept C168563851 @default.
• W2090907917 hasConcept C197934379 @default.
• W2090907917 hasConcept C204787440 @default.
• W2090907917 hasConcept C27081682 @default.
• W2090907917 hasConcept C2776608144 @default.
• W2090907917 hasConcept C2776694085 @default.
• W2090907917 hasConcept C2779289229 @default.
• W2090907917 hasConcept C2779384505 @default.
• W2090907917 hasConcept C2779901536 @default.
• W2090907917 hasConcept C42219234 @default.
• W2090907917 hasConcept C555293320 @default.
• W2090907917 hasConcept C71924100 @default.
• W2090907917 hasConcept C83849319 @default.
• W2090907917 hasConcept C87813604 @default.
• W2090907917 hasConceptScore W2090907917C126322002 @default.
• W2090907917 hasConceptScore W2090907917C134018914 @default.
• W2090907917 hasConceptScore W2090907917C138496976 @default.
• W2090907917 hasConceptScore W2090907917C142724271 @default.
• W2090907917 hasConceptScore W2090907917C15744967 @default.
• W2090907917 hasConceptScore W2090907917C168563851 @default.

• next